CAML does not modulate tetherin-mediated restriction of HIV-1 particle release

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Ali, Mohammed S ^a,b   Hammonds, Jason ^a   Ding, Lingmei ^a   Spearman, Paul ^a  

^a EMORY UNIVERSITY   (United States)

^b WILLIAM BEAUMONT ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CALCIUM MODULATING CYCLOPHILIN LIGAND; INTERFERON; LIGAND; MEMBRANE PROTEIN; TETHERIN; UNCLASSIFIED DRUG; BST2 PROTEIN, HUMAN; CAMLG PROTEIN, HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LEUKOCYTE ANTIGEN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; VIRUS PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMAL CELL; ARTICLE; CELL LEVEL; CELL SURFACE; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; VIRUS ACTIVATION; VIRUS PARTICLE; ANIMAL; CELL LINE; CELL STRAIN COS1; CERCOPITHECUS; GENETIC TRANSFECTION; GENETICS; LEUKEMIA CELL LINE; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; VIRION; VIRUS REPLICATION; WESTERN BLOTTING;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; HELA CELLS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; JURKAT CELLS; MEMBRANE GLYCOPROTEINS; RNA INTERFERENCE; TRANSFECTION; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRION; VIRUS REPLICATION;

EID: 77749305015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009005     Document Type: Article

References (31)

1. Schwartz S, Felber BK, Fenyo EM, Pavlakis GN (1990) Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol 64: 5448-5456.
2. Arrigo SJ, Chen IS (1991) Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/vpu 2 RNAs. Genes Dev 5: 808-819.
3. Schubert U, Bour S, Ferrer-Montiel AV, Montal M, Maldarell F, et al. (1996) The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains. J Virol 70: 809-819.
4. Bour S, Schubert U, Strebel K (1995) The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol 69: 1510-1520.
5. Margottin F, Bour SP, Durand H, Selig L, Benichou S, et al. (1998) A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1: 565-574.
6. Schubert U, Strebel K (1994) Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol 68: 2260-2271.
7. Willey RL, Maldarelli F, Martin MA, Strebel K (1992) Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 66: 7193-7200.
8. Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM (1990) The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol 64: 621-629.
9. Neil SJ, Eastman SW, Jouvenet N, Bieniasz PD (2006) HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2: e39.
10. Schwartz MD, Geraghty RJ, Panganiban AT (1996) HIV-1 particle release mediated by Vpu is distinct from that mediated by p6. Virology 224: 302-309.
11. Varthakavi V, Smith RM, Bour SP, Strebel K, Spearman P (2003) Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci U S A 100: 15154-15159.
12. Neil SJ, Sandrin V, Sundquist WI, Bieniasz PD (2007) An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2: 193-203.
13. Neil SJ, Zang T, Bieniasz PD (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-430.
14. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, et al. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3: 245-252.
15. Varthakavi V, Heimann-Nichols E, Smith RM, Sun Y, Bram RJ, et al. (2008) Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu. Nat Med 14: 641-647.
16. Ishikawa J, Kaisho T, Tomizawa H, Lee BO, Kobune Y, et al. (1995) Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 26: 527-534.
17. Ohtomo T, Sugamata Y, Ozaki Y, Ono K, Yoshimura Y, et al. (1999) Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 258: 583-591.
18. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, et al. (2003) Bst-2/ HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4: 694-709.
19. Bartee E, McCormack A, Fruh K (2006) Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog 2: e107.
20. Bram RJ, Crabtree GR (1994) Calcium signalling in T cells stimulated by a cyclophilin B-binding protein. Nature 371: 355-358.
21. Holloway MP, Bram RJ (1996) A hydrophobic domain of Ca2+-modulating cyclophilin ligand modulates calcium influx signaling in T lymphocytes. J Biol Chem 271: 8549-8552.
22. Holloway MP, Bram RJ (1998) Co-localization of calcium-modulating cyclophilin ligand with intracellular calcium pools. J Biol Chem 273: 16346-16350.
23. Tran DD, Russell HR, Sutor SL, van Deursen J, Bram RJ (2003) CAML is required for efficient EGF receptor recycling. Dev Cell 5: 245-256.
24. Yuan X, Yao J, Norris D, Tran DD, Bram RJ, et al. (2008) Calcium-modulating cyclophilin ligand regulates membrane trafficking of postsynaptic GABA(A) receptors. Mol Cell Neurosci 38: 277-289.
25. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J (2009) Inhibition of Lassa and Marburg virus production by tetherin. J Virol 83: 2382-2385.
26. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, et al. (2009) Broadspectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 83: 1837-1844.
27. Gupta RK, Hue S, Schaller T, Verschoor E, Pillay D, et al. (2009) Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog 5: e1000443.
28. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, et al. (2009) Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 5: e1000429.
29. Dube M, Roy BB, Guiot-Guillain P, Mercier J, Binette J, et al. (2009) Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol 83: 4574-4590.
30. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, et al. (2009) Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 5: e1000300.
31. Bego MG, Dube M, Mercier J, Cohen EA (2009) Effect of calcium-modulating cyclophilin ligand on human immunodeficiency virus type 1 particle release and cell surface expression of tetherin. J Virol 83: 13032-13036.